Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Acquires 200,000 Shares

Share on StockTwits

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 200,000 shares of Opko Health stock in a transaction dated Tuesday, November 12th. The stock was bought at an average price of $1.44 per share, with a total value of $288,000.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $4,419,289.44. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Friday, November 8th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The stock was bought at an average price of $1.48 per share, with a total value of $74,000.00.
  • On Wednesday, November 6th, Phillip Md Et Al Frost purchased 350,000 shares of Opko Health stock. The stock was bought at an average price of $1.49 per share, with a total value of $521,500.00.
  • On Thursday, October 31st, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The stock was bought at an average price of $1.43 per share, with a total value of $71,500.00.
  • On Tuesday, October 29th, Phillip Md Et Al Frost purchased 200,000 shares of Opko Health stock. The stock was bought at an average price of $1.47 per share, with a total value of $294,000.00.
  • On Friday, October 25th, Phillip Md Et Al Frost purchased 2,000,000 shares of Opko Health stock. The stock was bought at an average price of $1.50 per share, with a total value of $3,000,000.00.

Opko Health stock opened at $1.43 on Friday. Opko Health Inc. has a 52 week low of $1.33 and a 52 week high of $3.93. The business has a 50-day simple moving average of $1.82 and a 200 day simple moving average of $1.99. The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.90 and a current ratio of 1.08.

Opko Health (NASDAQ:OPK) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.02). Opko Health had a negative return on equity of 14.42% and a negative net margin of 30.98%. The business had revenue of $228.80 million for the quarter, compared to analysts’ expectations of $225.40 million. During the same quarter in the previous year, the firm earned ($0.05) earnings per share. Opko Health’s quarterly revenue was down 8.4% compared to the same quarter last year. Analysts forecast that Opko Health Inc. will post -0.43 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the stock. Mackay Shields LLC boosted its holdings in shares of Opko Health by 4.2% in the 3rd quarter. Mackay Shields LLC now owns 452,550 shares of the biotechnology company’s stock worth $946,000 after purchasing an additional 18,200 shares in the last quarter. Gamco Investors INC. ET AL boosted its holdings in shares of Opko Health by 93.8% in the 3rd quarter. Gamco Investors INC. ET AL now owns 155,000 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 75,000 shares in the last quarter. California Public Employees Retirement System boosted its holdings in shares of Opko Health by 35.8% in the 3rd quarter. California Public Employees Retirement System now owns 681,627 shares of the biotechnology company’s stock worth $1,425,000 after purchasing an additional 179,782 shares in the last quarter. Commonwealth Equity Services LLC boosted its holdings in shares of Opko Health by 2.4% in the 3rd quarter. Commonwealth Equity Services LLC now owns 420,879 shares of the biotechnology company’s stock worth $879,000 after purchasing an additional 9,900 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Opko Health by 10.8% in the 3rd quarter. Rhumbline Advisers now owns 550,497 shares of the biotechnology company’s stock worth $1,151,000 after purchasing an additional 53,557 shares in the last quarter. Institutional investors and hedge funds own 24.58% of the company’s stock.

Several equities analysts have recently weighed in on the company. Barrington Research reiterated a “buy” rating and issued a $4.00 price target on shares of Opko Health in a research report on Thursday, September 12th. ValuEngine upgraded Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. BidaskClub cut Opko Health from a “hold” rating to a “sell” rating in a research report on Tuesday, October 29th. Finally, Zacks Investment Research upgraded Opko Health from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research report on Friday, October 18th.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Further Reading: Channel Trading

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analyzing CV Sciences  & Regulus Therapeutics
Analyzing CV Sciences & Regulus Therapeutics
Allison Transmission Holdings Inc  Sees Significant Increase in Short Interest
Allison Transmission Holdings Inc Sees Significant Increase in Short Interest
Short Interest in Air Lease Corp  Decreases By 8.2%
Short Interest in Air Lease Corp Decreases By 8.2%
Armada Hoffler Properties Inc  Sees Large Drop in Short Interest
Armada Hoffler Properties Inc Sees Large Drop in Short Interest
Short Interest in Arrow Electronics, Inc.  Increases By 6.0%
Short Interest in Arrow Electronics, Inc. Increases By 6.0%
Arch Coal Inc  Short Interest Down 6.1% in November
Arch Coal Inc Short Interest Down 6.1% in November


© 2006-2019 Ticker Report